TY - JOUR
T1 - The 2024 British Society for Rheumatology guideline for management of systemic sclerosis—executive summary
AU - Denton, Christopher
AU - Lorenzis, Enrico De
AU - Roblin, Elen
AU - Goldman, Nina
AU - Alcacer-Pitarch, Begonya
AU - Blamont, Emma
AU - Buch, Maya
AU - Carulli, Maresa
AU - Cotton, Caroline
AU - Galdo, Francesco Del
AU - Derrett-Smith, Emma
AU - Douglas, Karen
AU - Farrington, Sue
AU - Fligelstone, Kim
AU - Gompels, Luke
AU - Griffiths, Bridget
AU - Herrick, Ariane
AU - Hughes, Michael
AU - Pain, Clare E
AU - Pantano, Georgina
AU - Pauling, John D.
AU - Prabu, Athiveeraramapandian
AU - O’Donoghue, Nuala
AU - Renzoni, Elisabetta A
AU - Royle, Jeremy
AU - Samaranayaka, Muditha
AU - Spierings, Julia
AU - Tynan, Aoife
AU - Egerton-Warburton, Louise
AU - Ong, Voon
PY - 2024/9/11
Y1 - 2024/9/11
N2 - This guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Development Group comprising healthcare professionals with expertise in SSc and people with lived experience, as well as patient organization representatives. It is an update of the previous 2015 SSc guideline. The recommendations were developed and agreed by the group and are underpinned by published evidence, assessed by systematic literature review and reinforced by collective expert opinion of the group. It considers all aspects of SSc including general management, treatment of organ-based complications, including cardiopulmonary, renal and gastrointestinal tract manifestations, as well as broader impact of disease. Whilst it is focused on adults with SSc we expect that the guideline will be relevant to people of all ages and expert input and review by paediatric rheumatologists and other relevant specialists considered where the guideline was, or may not be, applicable to young people with SSc and juvenile-onset disease. In addition to providing guidance on disease assessment and management the full guideline also considers service organization within the National Health Service and future approaches to audit of the guideline. The lay summary that accompanies this abstract can be found in Supplemental information 1.
AB - This guideline was developed according to the British Society for Rheumatology Guidelines Protocol by a Guideline Development Group comprising healthcare professionals with expertise in SSc and people with lived experience, as well as patient organization representatives. It is an update of the previous 2015 SSc guideline. The recommendations were developed and agreed by the group and are underpinned by published evidence, assessed by systematic literature review and reinforced by collective expert opinion of the group. It considers all aspects of SSc including general management, treatment of organ-based complications, including cardiopulmonary, renal and gastrointestinal tract manifestations, as well as broader impact of disease. Whilst it is focused on adults with SSc we expect that the guideline will be relevant to people of all ages and expert input and review by paediatric rheumatologists and other relevant specialists considered where the guideline was, or may not be, applicable to young people with SSc and juvenile-onset disease. In addition to providing guidance on disease assessment and management the full guideline also considers service organization within the National Health Service and future approaches to audit of the guideline. The lay summary that accompanies this abstract can be found in Supplemental information 1.
KW - scleroderma
KW - systemic sclerosis
KW - interstitial lung disease
KW - guideline
KW - management
U2 - 10.1093/rheumatology/keae390
DO - 10.1093/rheumatology/keae390
M3 - Article
SN - 1462-0324
VL - 63
SP - 2948
EP - 2955
JO - Rheumatology
JF - Rheumatology
IS - 11
ER -